Bedrijfsoverzicht
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical enterprise focused on developing gene and cell therapies that utilize precision technology to address specific diseases within immuno-oncology, autoimmune disorders, and infectious disease domains. The company operates within the broader healthcare sector, specifically functioning as a biotechnology firm, which positions it as a specialized entity engaged in high-risk, high-reward research and development activities rather than established manufacturing or distribution of mature pharmaceutical products. The entity employs approximately 160 individuals and holds a total market capitalization valued at $1.47 billion, reflecting significant market interest despite its early-stage operational profile. While the company reported annual revenue of $9.68 million over the trailing twelve months, the substantial market capitalization relative to these revenue figures indicates that the market is pricing in significant future potential and intellectual property value rather than current cash-flow generation, a common characteristic for clinical-stage biotechnology firms where valuation is driven by pipeline assets and potential regulatory approval pathways.
Financiële gezondheid
Over the trailing twelve months, Precigen, Inc. generated revenue of $9.68 million while reporting a net income loss of $429,641,984 and an EBITDA deficit of $103,401,000, highlighting a profound discrepancy where operating expenses and research costs vastly exceed revenue generation. The company's free cash flow stands at -$53,353,876, indicating a continuous cash burn rate that necessitates external financing or existing cash reserves to sustain ongoing development programs and operational activities. The financial statement presents extreme margin compression with a gross margin of 0.0%, an operating margin of -474.6%, and a profit margin of 0.0%, all of which signal that the business model is currently unsustainable on a commercial basis and relies entirely on future product approvals to achieve profitability. In terms of liquidity, the company holds $97.86 million in cash against $98.29 million in debt, resulting in a debt-to-equity ratio of 470.04%, which suggests a highly leveraged balance sheet structure typical of pre-revenue biotech companies but one that requires careful management of refinancing risks. Short-term liquidity is supported by a current ratio of 3.09, indicating that the company possesses sufficient current assets to cover its current liabilities multiple times over, providing a temporary buffer against immediate solvency pressures. Furthermore, the return on equity is recorded at -572.0% and the return on assets at -44.3%, metrics that mathematically reflect the net loss position and demonstrate that management has not yet generated positive returns on shareholder capital or the asset base due to the lack of commercial product sales.
Waarderingsbeoordeling
Valuation multiples for Precigen, Inc. reflect its status as a loss-making entity, evidenced by a trailing P/E ratio that is listed as N/A and a forward P/E of -18.91, the latter implying that analysts project continued negative earnings in the near future or are adjusting for expected dilution and cash burn rather than immediate profitability. The price-to-book ratio is exceptionally high at 70.51, suggesting that the market assigns a massive premium to the company's intangible assets, such as its patent portfolio and clinical data, which far outweigh the book value of its tangible assets. Alternative valuation metrics further illustrate the disconnect between current financial performance and market price, with a price-to-sales ratio of 152.04 and an EV/EBITDA of -14.24, indicating that investors are valuing the company based on its pipeline potential rather than sales efficiency or earnings power. The stock's trading range over the last year spans from a 52-week low of $1.23 to a high of $5.47, providing a volatility context where the current market price must be interpreted against this established band to gauge recent momentum relative to historical extremes. The stock exhibits a beta of 1.12, meaning its price volatility is slightly higher than the broader market average, a characteristic often found in small-cap biotechnology stocks where single clinical trial outcomes can drive significant price swings regardless of fundamental financial ratios.
Growth & Income
The company demonstrates aggressive top-line expansion with a revenue growth rate of 283.6% year-over-year, whereas earnings growth is listed as N/A due to the persistent net losses, implying that revenue increases are currently being consumed by escalating research and development expenditures rather than translating into bottom-line profit. As a non-dividend payer, Precigen, Inc. maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all available capital to fund its clinical trials and operational expenses rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that prioritize funding their therapeutic platforms, such as the AdenoVerse platform, to advance candidates through regulatory hurdles before seeking commercialization. The overall growth and income profile is defined by rapid revenue scaling coupled with significant cash consumption and zero dividend distribution, positioning the equity as a speculative growth vehicle dependent on future successful product launches to alter its financial trajectory and valuation multiple.